A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer
The purpose of this study is to assess the feasibility of combined administration of different LBH589 dosages with radiotherapy in order to establish the dosage to be evaluated in future studies.
Prostate Cancer|Head & Neck Cancer|Esophageal Cancer
DRUG: panobinostat
Establish Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD), 1 to 28 days
Safety profile of oral LBH589 when given in combination with standard Radiotherapy, min 1 month
The purpose of this study is to assess the feasibility of combined administration of different LBH589 dosages with radiotherapy in order to establish the dosage to be evaluated in future studies.